tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2017 Nov 10. doi: 10.1111/irv.12520. [Epub ahead of print]
[h=1]2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.[/h] Kissling E[SUP]1[/SUP], Valenciano M[SUP]1[/SUP], Pozo F[SUP]2[/SUP], Vilcu AM[SUP]3[/SUP], Reuss A[SUP]4[/SUP], Rizzo C[SUP]5[/SUP], Larrauri A[SUP]6,[/SUP][SUP]7[/SUP], Horv?th JK[SUP]8[/SUP], Brytting M[SUP]9[/SUP], Domegan L[SUP]10[/SUP], Korczyńska M[SUP]11[/SUP], Meijer A[SUP]12[/SUP], Machado A[SUP]13[/SUP], Ivanciuc A[SUP]14[/SUP], Vi?ekruna Vučina V[SUP]15[/SUP], van der Werf S[SUP]16[/SUP], Schweiger B[SUP]17[/SUP], Bella A[SUP]5[/SUP], Gherasim A[SUP]6[/SUP], Ferenczi A[SUP]8[/SUP], Zakikhany K[SUP]9[/SUP], O Donnell J[SUP]10[/SUP], Paradowska-Stankiewicz I[SUP]11[/SUP], Dijkstra F[SUP]12[/SUP], Guiomar R[SUP]13[/SUP], Lazar M[SUP]14[/SUP], Kurečić Filipović S[SUP]15[/SUP], Johansen K[SUP]18[/SUP], Moren A[SUP]1[/SUP]; I-MOVE/I-MOVE+ study team[SUP]19[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
[h=4]METHODS:[/h] We used the test negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.
[h=4]RESULTS:[/h] We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0-14, 15-64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively.
[h=4]CONCLUSIONS:[/h] VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Case control study; Influenza; influenza vaccine; multicentre study; vaccine effectiveness
PMID: 29125681 DOI: 10.1111/irv.12520
Free full text
[h=1]2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.[/h] Kissling E[SUP]1[/SUP], Valenciano M[SUP]1[/SUP], Pozo F[SUP]2[/SUP], Vilcu AM[SUP]3[/SUP], Reuss A[SUP]4[/SUP], Rizzo C[SUP]5[/SUP], Larrauri A[SUP]6,[/SUP][SUP]7[/SUP], Horv?th JK[SUP]8[/SUP], Brytting M[SUP]9[/SUP], Domegan L[SUP]10[/SUP], Korczyńska M[SUP]11[/SUP], Meijer A[SUP]12[/SUP], Machado A[SUP]13[/SUP], Ivanciuc A[SUP]14[/SUP], Vi?ekruna Vučina V[SUP]15[/SUP], van der Werf S[SUP]16[/SUP], Schweiger B[SUP]17[/SUP], Bella A[SUP]5[/SUP], Gherasim A[SUP]6[/SUP], Ferenczi A[SUP]8[/SUP], Zakikhany K[SUP]9[/SUP], O Donnell J[SUP]10[/SUP], Paradowska-Stankiewicz I[SUP]11[/SUP], Dijkstra F[SUP]12[/SUP], Guiomar R[SUP]13[/SUP], Lazar M[SUP]14[/SUP], Kurečić Filipović S[SUP]15[/SUP], Johansen K[SUP]18[/SUP], Moren A[SUP]1[/SUP]; I-MOVE/I-MOVE+ study team[SUP]19[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.
[h=4]METHODS:[/h] We used the test negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.
[h=4]RESULTS:[/h] We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0-14, 15-64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively.
[h=4]CONCLUSIONS:[/h] VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Case control study; Influenza; influenza vaccine; multicentre study; vaccine effectiveness
PMID: 29125681 DOI: 10.1111/irv.12520
Free full text